Literature DB >> 1327178

Relation between leukocyte counts and cortisol secretion in CML patients undergoing combined TNF alpha/IFN alpha therapy.

M Nagel-Hiemke1, C Hiemke, G Kummer, T Moritz, H Müller, S Seeber, N Niederle.   

Abstract

During long-term interferon alpha-2b (IFN) therapy of Philadelphia chromosome-positive chronic myelogenous leukemia (CML) patients, short-term effects of tumor necrosis factor alpha (TNF) on peripheral leukocyte counts, as well as cortisol and corticotropin (ACTH) release were studied. TNF (40-160 micrograms/m2) was given as a 2-h infusion on 5 consecutive days every 3 weeks, in addition to s.c. daily IFN injections (4 mio U/m2), to four (two male/two female) patients, who had been treated for more than 8 months with IFN and additionally for 0-7 months with TNF. Leukocyte counts, cortisol, and ACTH were determined at 30-min intervals between 4 p.m. and midnight. Profiles were determined the day before and on day 1 of TNF therapy. Leukocyte numbers decreased 30 min after start of TNF administration and increased 30-60 min later with a rebound until the next TNF application. The increase of leukocyte counts was due mostly to neutrophil granulocytes. ACTH levels increased 30 min, cortisol 60 min, and leukocyte counts 90 min after start of TNF infusion. Metopirone, an inhibitor of cortisol synthesis given to one patient, suppressed the TNF-induced stimulation of cortisol secretion and subsequent increase of leukocyte counts, while ACTH blood levels were enhanced. It was concluded that leukocyte count increases after TNF/IFN administration might be related to TNF-evoked cortisol secretion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327178     DOI: 10.1007/bf01695809

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  39 in total

1.  LEUKOKINETIC STUDIES. X. BLOOD GRANULOCYTE KINETICS IN CHRONIC MYELOCYTIC LEUKEMIA.

Authors:  J W ATHENS; S O RAAB; O P HAAB; D R BOGGS; H ASHENBRUCKER; G E CARTWRIGHT; M M WINTROBE
Journal:  J Clin Invest       Date:  1965-05       Impact factor: 14.808

2.  Identification of an inducible endothelial-leukocyte adhesion molecule.

Authors:  M P Bevilacqua; J S Pober; D L Mendrick; R S Cotran; M A Gimbrone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

3.  Treatment of essential thrombocythaemia with interferon alpha-2b.

Authors:  D May; U B Wandl; N Niederle
Journal:  Lancet       Date:  1989-01-14       Impact factor: 79.321

4.  Interferon-alpha-2-induced stimulation of ACTH and cortisol secretion in man.

Authors:  H Müller; E Hammes; C Hiemke; G Hess
Journal:  Neuroendocrinology       Date:  1991-11       Impact factor: 4.914

5.  Differential blood counts in certain adrenal cortical disorders (Cushing's syndrome, Addison's disease and panhypopituitarism).

Authors:  F A DE LA BALZE; E C REIFENSTEIN; F ALBRIGHT
Journal:  J Clin Endocrinol Metab       Date:  1946-04       Impact factor: 5.958

6.  Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone.

Authors:  D C Dale; A S Fauci; I V Guerry D; S M Wolff
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

7.  IFN-alpha in vivo enhances tumor necrosis factor receptor levels on hairy cells.

Authors:  C Billard; F Sigaux; J Wietzerbin
Journal:  J Immunol       Date:  1990-09-15       Impact factor: 5.422

8.  Antileukemic effect of recombinant tumor necrosis factor alpha in vitro and its modulation by alpha and gamma interferons.

Authors:  M Beran; K B McCredie; M J Keating; J U Gutterman
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

9.  Phase I study of recombinant tumor necrosis factor in cancer patients.

Authors:  M Blick; S A Sherwin; M Rosenblum; J Gutterman
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

Review 10.  Passage of immunomodulators across the blood-brain barrier.

Authors:  J T Stitt
Journal:  Yale J Biol Med       Date:  1990 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.